Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6901 to 6915 of 8905 results

  1. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) (DG23)

    This guidance has been updated and replaced by NICE healthtech guidance 630.

    Withdrawn guidance

  2. ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)

    We have moved Diagnostics guidance 24 to become HealthTech guidance 413. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. High-throughput non-invasive prenatal testing for fetal RHD genotype (DG25)

    We have moved Diagnostics guidance 25 to become HealthTech guidance 420. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Integrated multiplex PCR tests for identifying gastrointestinal pathogens in people with suspected gastroenteritis (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B assay) (DG26)

    July 2022: The guidance has been withdrawn because PCR tests now form part of standard care. Since the diagnostics guidance was published, expert advice suggests that clinical practice has moved on; PCR testing using a centralised approach is widely available in the NHS and adoption is growing. The UK standards for Microbiology Investigation also provide additional support for the PCR-based diagnostic tests.

    Withdrawn guidance

  5. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

    We have moved Diagnostics guidance 27 to become HealthTech guidance 430. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (DG29)

    We have moved Diagnostics guidance 29 to become HealthTech guidance 441. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (DG3)

    We have moved Diagnostics guidance 3 to become HealthTech guidance 281. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (DG28)

    We have moved Diagnostics guidance 28 to become HealthTech guidance 438. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

    This guidance has been updated and replaced by NICE healthtech guidance 690.

    Withdrawn guidance

  10. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

    This guidance has been updated and replaced by NICE diagnostics guidance 58.

    Withdrawn guidance

  11. Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

    We have moved Diagnostics guidance 33 to become HealthTech guidance 476. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

    We have moved Diagnostics guidance 31 to become HealthTech guidance 453. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

    We have moved Diagnostics guidance 32 to become HealthTech guidance 467. This is to better reflect the NICE HealthTech programme, which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

    We have moved Diagnostics guidance 35 to become HealthTech guidance 508. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

    We have moved Diagnostics guidance 37 to become HealthTech guidance 530. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance